NVCR News and Press, NovoCure Limited From 07/31/19

NovoCure ( NVCR ) reported strong Q2 results, beating both revenue and EPS estimates. Part of the beat was a non-recurring $5 million revenue benefit, but Optune has delivered strong sequential and Y/Y growth even if the one-time benefit is excluded. NovoCure saw good news on all fronts in...

KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Outperform rating and $31 (83% upside) price target at SVB Leerink. More news on: KalVista Pharmaceuticals, Inc., Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...

CRISPR Therapeutics ( CRSP +0.8% ) initiated with Buy rating and $72 price target at Canaccord Genuity. More news on: CRISPR Therapeutics AG, Cue Biopharma, Inc., DENTSPLY SIRONA Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Novocure Limited (NVCR) Q2 2019 Earnings Conference Call July 25, 2019 8:00 AM ET Company Participants Ashley Cordova – Senior Vice President-Finance and Investor Relations Bill Doyle – Executive Chairman Asaf Danziger – Chief Executive Officer Ely Benaim &...

The following slide deck was published by NovoCure Limited in conjunction with their 2019 Q2 earnings Read more ...

NovoCure ( NVCR ) Q2 results : Revenues: $86.7M (+41.0%). More news on: NovoCure Limited, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

NovoCure (NASDAQ: NVCR ): Q2 GAAP EPS of -$0.01 beats by $0.06 . More news on: NovoCure Limited, Earnings news and commentary, Healthcare stocks news, Read more ...

Quarterly net revenues of $86.7 million, representing 41 percent growth versus the second quarter 2018 The NovoTTF-100L™ System FDA approved to treat malignant pleural mesothelioma in combination with standard chemotherapies, Novocure’s first FDA-approved torso indication...

AAL , AAN , AB , ABB , AEP , AIMC , ALKS , ALLE , APD , ARD , ASPS , AUO , AXE , AZN , BANC , BAX , BC , BGCP , BMY , BUD , BWA , CCJ , CFR , CMCSA , CMS , COLB , CPG , CRI , CRR , CVE , DBD , DLX , ENTG , EQT , FAF , FCN , FDC , GLOP , GPI , GRA , H...

Introduction I first introduced the story of NovoCure ( NVCR ) in November 2017 when shares were trading below $20. Today, shares of NovoCure trade near $70. I was interested in NovoCure's new modality to treat cancer: the use of tumor treating fields that work to upset broken &am...